November 10, 2023 News by Marisa Wexler, MS CSF protein levels at diagnosis may help predict MS long-term outcomes Levels of proteins in the liquid that surrounds the brain and spinal cord, called the cerebrospinal fluid (CSF), can help predict disease activity and disability worsening for people with multiple sclerosis (MS), a study reports. “We identified several promising protein biomarkers which could be used to predict short-term activity…
October 26, 2023 News by Patricia Inacio, PhD Losing sense of smell can predict MS relapse-independent progression Losing the sense of smell is associated with a higher likelihood of worse disease outcomes for people with multiple sclerosis (MS), according to a six-year follow-up study. Specifically, patients who are getting worse at identifying and discriminating odors are at higher risk of disability worsening, relapse-independent MS progression, and…
July 19, 2023 News by Margarida Maia, PhD Adhering to treatment is linked to better long-term outcomes People with multiple sclerosis (MS) who take their prescribed disease-modifying therapies (DMTs) as recommended have better long-term health outcomes and lower healthcare costs than those who donāt, a U.S. study finds. Adhering to treatment can help reduce relapses, slow disease progression, and reduce the economic burden on both…
May 17, 2023 News by Marisa Wexler, MS Stem cell therapy may do most good when given early People with multiple sclerosis (MS) who have never received treatment with a disease-modifying therapy tend to have better long-term outcomes after stem cell transplant, according to a recent report from a center in Mexico. The findings suggest that stem cell therapy may be most beneficial when given…
January 24, 2023 News by Marisa Wexler, MS Better Standards Needed for NICE Evaluation of MS Treatments: Study In evaluating potential treatments for multiple sclerosis (MS) over the past two decades, England’s National Institute for Health and Care Excellence (NICE) made differing assumptions about whether and how the therapies’ effects will diminish over time. Such assumptions have a significant impact in estimating a therapy’s cost-effectiveness ā a…
December 5, 2022 News by Marisa Wexler, MS After Stabilizing Treatment, Disease Activity Predicts Outcome in Study Assessing disease activity from the first to second year after a diagnosis of multiple sclerosis (MS), once treatment has been initiated and stabilized, can help predict long-term disability outcomes. That’s according to the study, “Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term…
December 2, 2022 News by Margarida Maia, PhD Eating Lots of Acidic Foods Linked to Worse, Longer Depression in MS Eating a lot of acidic foods like meat, eggs, cheese, and grains ā and fewer alkaline ones, such as fruits, vegetables, and milk ā is significantly associated with worse depression scores over five years among people with multiple sclerosis (MS), a study found. “The level of depression at the…
November 10, 2022 News by Marisa Wexler, MS Measuring Growth of Lesions in MS Better Predicts Disability Progression Measuring how lesions get bigger over time in multiple sclerosis (MS) can predict long-term disability progression more accurately than other lesion-based assessments, a new study reports. “Enlargement of T2 [total] lesions, and specifically of its volume, … is more strongly associated with long-term disability progression compared to other…
May 26, 2017 News by Patricia Silva, PhD #CMSC17 – Relapse After First Lemtrada Course No Indication of Poor Long-Term Outcome, Study Finds Multiple sclerosis (MS) patients who experienced a relapse between their first and second rounds of Lemtrada (alemtuzumab) had good treatment outcomes over the long run, according to a Phase 3 clinical trial. Those who relapsed after their first round ended up with annual relapse rates similar to those who didn’t…